NSEGeneral Updates3 Sept 2026 · 3 Sept 2026, 02:35 pm
General Updates
Piramal Pharma Limited · PPLPHARMA
✦ AI SummaryESG
Piramal Pharma Limited has received an ESG rating of 65 from NSE Sustainability Ratings and Analytics Limited for FY 2025-26, marking an improvement over the previous score of 64.
Analysis Scores
Earnings Impact1/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
Attachments (1)
📄pdf
Download →
PIRAMALPHARMA_03092026143331_ESG_RatingSEintimation.pdf
View document text
Date: 3rd September, 2026
BSE Limited National Stock Exchange of India Limited
P. J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla
Complex, Mumbai- 400 001 Bandra (East), Mumbai - 400 051
BSE scrip code: 543635 NSE Symbol: PPLPHARMA
Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015
(‘SEBI Listing Regulations’) – ESG Rating
Dear Sir / Madam,
With reference to the captioned subject, please note that as per the information
received by the Company on September 03, 2026, NSE Sustainability Ratings and
Analytics Limited (‘NSE Sustainability’), has assigned an Environment, Social and
Governance (‘ESG’) Rating of ‘65’ for the Company for the FY 2025-26 based on
data made available by the Company in public domain for that year, marking an
improvement over previous score of 64, reflecting the Company's ongoing
commitment to sustainability and responsible operations.
The link for the rating as published is also available on the website of NSE
Sustainability - NSE Sustainability Ratings & Analytics.
Please note that the Company has not engaged NSE Sustainability for ESG Rating.
NSE Sustainability has voluntarily prepared the report considering the ESG factors
reported by the Company.
This intimation is also being uploaded on the website of the Company at
https://www.piramalpharma.com/.
Kindly treat this intimation for your information and record.
Thank you.
Yours truly,
For Piramal Pharma Limited
Maneesh Sharma
Company Secretary & Compliance Officer
Piramal Pharma Limited
CIN: L24297MH2020PLC338592
Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No.
+91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com
www.piramalpharma.com